DATE OF RELEASE/EXPIRATION
The enduring material will be available from September 10, 2021 to September 10, 2022Jointly provided by Consortium of Multiple Sclerosis Centers (CMSC) and PlatformQ Health Education, LLC (PQHE).
CREDIT AVAILABLE
Physicians – 0.25 AMA PRA Category 1 Credit(s)™
Nurses – 0.25 contact hours of nursing continuing professional development (NCPD)
Pharmacists – 0.25 contact hours of continuing pharmacy education credit
PAs – 0.25 AAPA Category 1 CME credit
All other healthcare professionals completing this course will be issued a statement of participation.
TARGET AUDIENCE
This activity has been designed to meet the educational needs of physicians, pharmacists, nursing professionals, PAs, and other members of the healthcare team involved in the management of patients with MS.
LEARNING OBJECTIVES
Upon completing this activity, participants should be better able to:
- Consider patient’s disease activity, patient factors, and treatment goals and preferences to identify patient populations and scenarios in which high-efficacy DMTs are appropriate
- Assess recent data on the impact of DMTs on cognition in MS
FACULTY
Robert K. Shin, MD, FANA, FAAN
Professor, Department of Neurology
MedStar Georgetown University Hospital
Director, Georgetown Multiple Sclerosis and Neuroimmunology Center
Georgetown University Medical Center
Lilyana Amezcua, MD, MS, FAAN
Associate Professor of Neurology
Multiple Sclerosis Fellowship Program Director
Multiple Sclerosis Comprehensive Care and Research Group
USC, Keck School of Medicine
ACKNOWLEDGEMENT
This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, and Sanofi Genzyme.